- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
Patent holdings for IPC class C07D 241/08
Total number of patents in this class: 390
10-year publication summary
28
|
37
|
22
|
22
|
16
|
34
|
25
|
24
|
28
|
5
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
MannKind Corporation | 531 |
52 |
Massachusetts Institute of Technology | 9795 |
16 |
Suntory Holdings Limited | 1846 |
9 |
California Institute of Technology | 3884 |
8 |
Cv6 Therapeutics (NI) Limited | 31 |
8 |
Evonik Operations GmbH | 3879 |
8 |
Promentis Pharmaceuticals, Inc. | 16 |
7 |
BASF SE | 19740 |
6 |
Ampio Pharmaceuticals, Inc. | 46 |
6 |
Cytokinetics, Inc. | 259 |
6 |
New York University | 1635 |
6 |
Merck Sharp & Dohme LLC | 3689 |
6 |
F. Hoffmann-La Roche AG | 7958 |
5 |
Translate bio, Inc. | 394 |
5 |
VALO Health, Inc. | 147 |
5 |
Gen1e Lifesciences Inc. | 16 |
5 |
Glaxo Group Limited | 4496 |
4 |
Janssen Pharmaceutica N.V. | 3839 |
4 |
University of Southern California | 2016 |
4 |
Dong-A Pharmaceutical Co., Ltd. | 65 |
4 |
Other owners | 216 |